GI Innovation Inc.
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2017 and listed on KOSDAQ in 2023, GI Innovation is a biotech company developing next-generation immunotherapies based on fusion protein technology. Its core pipeline includes the immuno-oncology candidates GI-101 and GI-102, the allergy treatment GI-301, and the metabolic immuno-oncology candidate GI-108, discovered and produced through its proprietary GI-SMART™ platform (SMART-Selex™ and SMART-cLego™). The company has completed three global licensing deals, including GI-101 to China's Simcere Pharmaceutical for USD 790 million, GI-301 to Yuhan Corporation for KRW 1,409 billion (global rights excluding Japan) plus a further USD 221 million Japan-rights deal in October 2023, along with a co-development clinical agreement with MSD (Merck & Co.).
Regulatory approvals
1 Orphan Drug designations · 2025
- OrphanGI-102(CD80-IgG4 Fc-IL2v3)2025-01-15Orphan Drug designation · in development20240237740
Clinical trials
data.go.kr5 MFDS clinical trial authorisations · 2021–2026 (Phase 1/2 3 · Phase 2a 1 · Phase 1/2a 1)
- Phase 1/2GI-1022026-05-29
2 trial sites
- Phase 2aGI-1022026-02-23
1 trial site
- Phase 1/2aGI-1082024-12-11
3 trial sites
- Phase 1/2GI-1022023-02-20
6 trial sites
- Phase 1/2GI-1012021-04-21
9 trial sites
R&D and key agreements
Source: DART corporate disclosureGI-101 · 면역항암 · 임상 · Selected for a KRW 7 billion clinical program grant from the Korea Drug Development Fund (KDDF) and named to the 2020 National R&D Excellence 100 list.
GI-102 · 면역항암 · 임상 · Selected for a KRW 6.4 billion clinical program grant from the Korea Drug Development Fund (KDDF).
GI-301 · 알레르기 · 임상 · Licensed out global rights excluding Japan to Yuhan Corporation at the preclinical stage, followed by an additional licensing deal for Japan development and commercialization rights in October 2023.
GI-108 · 대사면역항암 · 임상 · Selected for a KRW 2 billion preclinical program grant from the Korea Drug Development Fund (KDDF).
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
KOSDAQ-listed biopharma developing the BVAC cancer immunotherapy vaccine series and the AdCLD-CoV19-1 COVID-19 vaccine.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition